Tiller Private Wealth Inc. Makes New $295,000 Investment in Johnson & Johnson $JNJ

Key Points

• Tiller Private Wealth Inc. has made a new investment of approximately $295,000 in Johnson & Johnson, acquiring 1,927 shares in the second quarter.
• Johnson & Johnson reported earnings per share of $2.77, beating estimates, and a quarterly revenue of $23.74 billion, marking a 5.8% increase year-over-year.
• The company recently declared a quarterly dividend of $1.30 per share, yielding approximately 2.9% annually, with a payout ratio of 55.61%.

Tiller Private Wealth Inc. bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 1,927 shares of the company's stock, valued at approximately $295,000.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.1%

Shares of NYSE:JNJ opened at $179.69 on Monday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $174.41 and its two-hundred day moving average is $162.05. The company has a market cap of $432.75 billion, a PE ratio of 19.22, a P/E/G ratio of 2.29 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on JNJ shares. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, UBS Group increased their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $181.40.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.